ArticleChildren (Basel, Switzerland)2019
Pathophysiology of Atopic Dermatitis and Psoriasis: Implications for Management in Children.
Article in Children (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Rademikibart (CBP-201), a next-generation monoclonal antibody targeting human IL-4Rα: Two phase I randomized trials, in healthy individuals and patients with atopic dermatitis.Clinical and translational science · 2023Trial
- Device-derived skin moisture, oil and softness scores in infants and young children with atopic dermatitis: a prospective case-control study.BMC pediatrics · 2026Article
- Plant-derived extracellular vesicles as tools and targets for inflammatory diseases.Journal of nanobiotechnology · 2026Review
- A Mobile App to Enhance Awareness of Vaccination in Adults With Psoriasis and Atopic Dermatitis: Development and Preliminary Evaluation Study.JMIR formative research · 2025Article
- The Supporting Role of Hyperbaric Oxygen Therapy in Atopic Dermatitis Treatment.Journal of clinical medicine · 2025Review
- A Mini-Review on the Symptoms and Pathogenesis of Psoriasis and Recent Nanotechnological Developments in its Treatment Strategies.Current pharmaceutical design · 2025Review
- Skin Function Improvement and Anti-Inflammatory Effects of Goat Meat Extract.Foods (Basel, Switzerland) · 2024Article
- Article
- Pharmacokinetic Profile of Brepocitinib with Topical Administration in Atopic Dermatitis and Psoriasis Populations: Strategy to Inform Clinical Trial Design in Adult and Pediatric Populations.Pharmaceutical research · 2024Article
- Unraveling Atopic Dermatitis: Insights into Pathophysiology, Therapeutic Advances, and Future Perspectives.Cells · 2024Review
- Mind bomb 2 limits inflammatory dermatitis inPNAS nexus · 2024Article
- Knowledge, attitude, and practice of psoriatic arthritis among patients with psoriasis.Frontiers in medicine · 2024Article
- Immune disease dialogue of chemokine-based cell communications as revealed by single-cell RNA sequencing meta-analysis.Frontiers in systems biology · 2024Article
- IL-22RA2 Is a SMAD7 Target Mediating the Alleviation of Dermatitis and Psoriatic Phenotypes in Mice.The Journal of investigative dermatology · 2023Article
- Preclinical immunological characterization of rademikibart (CBP-201), a next-generation human monoclonal antibody targeting IL-4Rα, for the treatment of Th2 inflammatory diseases.Scientific reports · 2023Article
- Phytocannabinoids in the Pharmacotherapy of Psoriasis.Molecules (Basel, Switzerland) · 2023Review
- Chemokine Profile in Psoriasis Patients in Correlation with Disease Severity and Pruritus.International journal of molecular sciences · 2022Article
- Atopic Dermatitis is More than Skin Deep: A Commentary on Atopic Dermatitis and Review of Pertinent Publications fromChildren (Basel, Switzerland) · 2022Article
- Targeting therapeutic approaches and highlighting the potential role of nanotechnology in atopic dermatitis.Environmental science and pollution research international · 2022Review
- Pathophysiology, Management and Quality of Life in Atopic Dermatitis and Psoriasis-A Challenge for Patients and Their Families.Children (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Atopic dermatitis (AD) and psoriasis are chronic inflammatory skin diseases associated with a significant cutaneous and systemic burden of disease as well as a poor health-related quality of life. Here, we review the complex pathophysiology of both AD and psoriasis and discuss the implications for treatment with current state-of-the-art and emerging topical and systemic therapies. Both AD and psoriasis are caused by a complex combination of immune dysregulation, skin-barrier disruption, genetic factors, and environmental influences. Previous treatments for both diseases were limited to anti-inflammatory agents that broadly suppress inflammation. Emerging insights into relevant pathways, including recognition of the role of T-helper type 2 driven inflammation in AD and T-helper 1 and 17 driven inflammation in psoriasis, have led to a therapeutic revolution. There are a number of novel treatment options available for AD and psoriasis with many more currently under investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.